Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 29

1.

Increased expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 gag gene.

zur Megede J, Chen MC, Doe B, Schaefer M, Greer CE, Selby M, Otten GR, Barnett SW.

J Virol. 2000 Mar;74(6):2628-35.

2.
3.
4.

Evaluation of novel human immunodeficiency virus type 1 Gag DNA vaccines for protein expression in mammalian cells and induction of immune responses.

Qiu JT, Song R, Dettenhofer M, Tian C, August T, Felber BK, Pavlakis GN, Yu XF.

J Virol. 1999 Nov;73(11):9145-52.

5.

A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers.

Evans TG, Keefer MC, Weinhold KJ, Wolff M, Montefiori D, Gorse GJ, Graham BS, McElrath MJ, Clements-Mann ML, Mulligan MJ, Fast P, Walker MC, Excler JL, Duliege AM, Tartaglia J.

J Infect Dis. 1999 Aug;180(2):290-8.

PMID:
10395842
6.

Recombinant modified vaccinia virus Ankara-simian immunodeficiency virus gag pol elicits cytotoxic T lymphocytes in rhesus monkeys detected by a major histocompatibility complex class I/peptide tetramer.

Seth A, Ourmanov I, Kuroda MJ, Schmitz JE, Carroll MW, Wyatt LS, Moss B, Forman MA, Hirsch VM, Letvin NL.

Proc Natl Acad Sci U S A. 1998 Aug 18;95(17):10112-6.

7.
8.

Distinct cellular interactions of secreted and transmembrane Ebola virus glycoproteins.

Yang Z, Delgado R, Xu L, Todd RF, Nabel EG, Sanchez A, Nabel GJ.

Science. 1998 Feb 13;279(5353):1034-7.

9.

Replication-defective canarypox (ALVAC) vectors effectively activate anti-human immunodeficiency virus-1 cytotoxic T lymphocytes present in infected patients: implications for antigen-specific immunotherapy.

Ferrari G, Berend C, Ottinger J, Dodge R, Bartlett J, Toso J, Moody D, Tartaglia J, Cox WI, Paoletti E, Weinhold KJ.

Blood. 1997 Sep 15;90(6):2406-16.

10.

Efficient lysis of human immunodeficiency virus type 1-infected cells by cytotoxic T lymphocytes.

Yang OO, Kalams SA, Rosenzweig M, Trocha A, Jones N, Koziel M, Walker BD, Johnson RP.

J Virol. 1996 Sep;70(9):5799-806.

11.

In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector.

Naldini L, Blömer U, Gallay P, Ory D, Mulligan R, Gage FH, Verma IM, Trono D.

Science. 1996 Apr 12;272(5259):263-7.

PMID:
8602510
12.

Gene inoculation generates immune responses against human immunodeficiency virus type 1.

Wang B, Ugen KE, Srikantan V, Agadjanyan MG, Dang K, Refaeli Y, Sato AI, Boyer J, Williams WV, Weiner DB.

Proc Natl Acad Sci U S A. 1993 May 1;90(9):4156-60.

13.

Requirements for incorporation of Pr160gag-pol from human immunodeficiency virus type 1 into virus-like particles.

Smith AJ, Srinivasakumar N, Hammarskjöld ML, Rekosh D.

J Virol. 1993 Apr;67(4):2266-75.

14.

Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome.

Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod G, Borkowsky W, Farthing C, Ho DD.

J Virol. 1994 Jul;68(7):4650-5.

15.

HIV-specific cytotoxic T-cell activity in an HIV-exposed but uninfected infant.

Rowland-Jones SL, Nixon DF, Aldhous MC, Gotch F, Ariyoshi K, Hallam N, Kroll JS, Froebel K, McMichael A.

Lancet. 1993 Apr 3;341(8849):860-1.

PMID:
8096564
16.
17.

Use of DNAs expressing HIV-1 Env and noninfectious HIV-1 particles to raise antibody responses in mice.

Lu S, Santoro JC, Fuller DH, Haynes JR, Robinson HL.

Virology. 1995 May 10;209(1):147-54.

18.

Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics.

Klein MR, van Baalen CA, Holwerda AM, Kerkhof Garde SR, Bende RJ, Keet IP, Eeftinck-Schattenkerk JK, Osterhaus AD, Schuitemaker H, Miedema F.

J Exp Med. 1995 Apr 1;181(4):1365-72.

19.
20.

Persistent high frequency of human immunodeficiency virus-specific cytotoxic T cells in peripheral blood of infected donors.

Moss PA, Rowland-Jones SL, Frodsham PM, McAdam S, Giangrande P, McMichael AJ, Bell JI.

Proc Natl Acad Sci U S A. 1995 Jun 20;92(13):5773-7.

Supplemental Content

Support Center